Alembic Pharmaceuticals Limited declared first quarter earnings for fiscal 2027 in an exchange filing on Tuesday, August 4. The pharmaceutical company's net profit rose 12.1% to Rs 173 crore in the quarter from Rs 154 crore in the corresponding crore last year.
Revenue surged 25.7% to Rs 2,150 crore in the April to June quarter from Rs 1,711 crore in the same quarter previous year. In terms of operations, Ebitda rose 18% to Rs 332 crore in the quarter under review compared to Rs 281 crore. Ebitda margin contracted at 15.4% against 16.4% on an year on year basis.
Alembic Pharma - Q1 (Cons, YoY)
- Ebitda Margin At 15.4% Vs 16.4%
- Ebitda rises 18% to Rs 332 crore Vs Rs 281 crore
- Revenue surges 25.7% to Rs 2,150 crore Vs Rs 1,711 crore
- Net Profit rises 12.1% to Rs 173 crore Vs Rs 154 crore
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
